Following cue from the above in vitro experiments, we undertook in vivo studies of R-Cu to test its Cfs-degrading activity. We observed that R-Cu at very high molar ratios of R to Cu, i.e., at low concentration of Cu with respect to R, can 1) prevent LPS- and Adriamycin-induced Cfs surge in mice; 2) prevent lethality of mice challenged with LPS; 3) prevent DNA damaging effects of Adriamycin in visceral organs and prevention of neutropenia; 4) prevent lung metastasis in the B16-F10 mouse melanoma model.